openPR Logo
Press release

Severe Hypertriglyceridemia Pipeline and Clinical Trials Assessment (2023) | Companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, and Others

11-21-2023 08:01 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Severe Hypertriglyceridemia Pipeline

Severe Hypertriglyceridemia Pipeline

The report titled "Severe Hypertriglyceridemia Pipeline Insight 2023" by DelveInsight offers extensive information on more than 10+ companies and 10+ pipeline drugs in the field of Severe Hypertriglyceridemia. It presents detailed profiles of these drugs, encompassing both Severe Hypertriglyceridemia clinical trials and nonclinical stage products. The Severe Hypertriglyceridemia pipeline report also includes a thorough assessment of therapeutics based on product type, stage, route of administration, and molecule type. Additionally, it highlights the inactive pipeline products in this area.

The Severe Hypertriglyceridemia Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Severe Hypertriglyceridemia clinical trials studies, Severe Hypertriglyceridemia NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Severe Hypertriglyceridemia, licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.

To explore more information on the latest breakthroughs in the Severe Hypertriglyceridemia Pipeline treatment landscape of the report, click here @ Severe Hypertriglyceridemia Pipeline Outlook- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
• Over 10+ Severe Hypertriglyceridemia companies are evaluating 10+ Severe Hypertriglyceridemia pipeline therapies in various stages of development, and their anticipated acceptance in the Severe Hypertriglyceridemia market would significantly increase market revenue.
• The leading Severe Hypertriglyceridemia companies are working in the market such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Promising Severe Hypertriglyceridemia Pipeline Therapies in various stages of development include Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Regeneron Pharmaceuticals' evinacumab was approved under the brand name Evkeeza by FDA in February 2021 for homozygous familial hypercholesterolemia. Regeneron Pharmaceuticals' Evinacumab (also known as REGN1500) is an intravenous ANGPTL-3 Antibody. A recent Phase II trial showed monoclonal antibody evinacumab significantly reduced fasting triglycerides in patients with severe hypertriglyceridemia with acute pancreatitis. Evinacumab binds to angiopoietin-like protein 3 (ANGPTL3), a protein thought to play a role in cholesterol metabolism, inhibiting its function.
• Vupanorsen is an investigational antisense therapy by Pfizer for potential SHTG. Vupanorsen acts through a novel mechanism, targeting ANGPTL3, a genetically validated target of lipoprotein metabolism. Vupanorsen was developed using Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform. In a Phase 2a study, vupanorsen met the primary endpoint of significant reductions in TG levels and multiple secondary endpoints compared to placebo, with a favorable safety and tolerability profile.

Severe Hypertriglyceridemia Overview
Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to an increased risk of cardiovascular disease (CVD).

For further information, refer to the detailed Severe Hypertriglyceridemia Unmet Needs, Severe Hypertriglyceridemia Market Drivers, and Severe Hypertriglyceridemia Market Barriers, click here for Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Emerging Drugs Profile
• ARO-APOC3: Arrowhead Pharmaceuticals
• Olezarsen: Ionis Pharmaceuticals

Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
There are approx. 10+ Severe Hypertriglyceridemia companies are developing Severe Hypertriglyceridemia therapies. The Severe Hypertriglyceridemia companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals, Inc.

Request a sample and discover the recent advances in Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis and Medications, click here @ Severe Hypertriglyceridemia Treatment Landscape- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
• Severe Hypertriglyceridemia Assessment by Product Type
• Severe Hypertriglyceridemia by Stage and Product Type
• Severe Hypertriglyceridemia Assessment by Route of Administration
• Severe Hypertriglyceridemia by Stage and Route of Administration
• Severe Hypertriglyceridemia Assessment by Molecule Type
• Severe Hypertriglyceridemia by Stage and Molecule Type

Some of the companies in the Severe Hypertriglyceridemia Therapeutics Market include-
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others

Dive deep into rich insights for drugs for the Severe Hypertriglyceridemia Pipeline, click here @ Severe Hypertriglyceridemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Hypertriglyceridemia Pipeline Report
• Coverage- Global
• Severe Hypertriglyceridemia Companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Severe Hypertriglyceridemia Pipeline Therapies- Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Severe Hypertriglyceridemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Severe Hypertriglyceridemia Mergers and acquisitions, Severe Hypertriglyceridemia Licensing Activities @ Severe Hypertriglyceridemia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Severe Hypertriglyceridemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Olezarsen: Ionis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ARO-APOC3: Arrowhead Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Severe Hypertriglyceridemia Key Companies
21. Severe Hypertriglyceridemia Key Products
22. Severe Hypertriglyceridemia- Unmet Needs
23. Severe Hypertriglyceridemia- Market Drivers and Barriers
24. Severe Hypertriglyceridemia- Future Perspectives and Conclusion
25. Severe Hypertriglyceridemia Analyst Views
26. Severe Hypertriglyceridemia Key Companies
27. Appendix

Important Published Links-

https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Severe Hypertriglyceridemia Pipeline and Clinical Trials Assessment (2023) | Companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, and Others here

News-ID: 3295097 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Hypertriglyceridemia

Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Severe
Hypertriglyceridemia Therapeutics Market Detailed In New Research Report 2024 |S …
The most recent report published by CMI indicates that the "Hypertriglyceridemia Therapeutics Market 2024-2031" is likely to accelerate significantly in the next few years. The Hypertriglyceridemia Therapeutics Market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The Hypertriglyceridemia Therapeutics Market study includes information on market factors such as the market dynamics, drivers, restraints,
Hypertriglyceridemia Treatment Market Growing Rapidly by - Hikma Pharmaceuticals …
DataM Intelligence has published a new research report on "Hypertriglyceridemia Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF -
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms
Hypertriglyceridemia Treatment Market Size, Share, Trends, Growth, Volume and Fo …
The Hypertriglyceridemia Treatment Market is expected to grow at a high CAGR during the forecast period 2023-2030. North America region has the highest market share in the Hypertriglyceridemia Treatment Market, and it is further continuing its dominance during the forecast period. Browse Full Report at: https://www.datamintelligence.com/research-report/hypertriglyceridemia-treatment-market Our research report gives wide perceptions of the latest trends and development prospects of the market analysis, detailed segmentation analysis, volume, size, share, growth drives, and
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms